

Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis

NCT06097832

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Nexcella Inc.
Enrollment	40 participants

Key Eligibility Criteria

Inclusion (13)

- e18years of age.
 - Voluntarily signed informed consent form (ICF).
 - Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
 - Histologically proven systemic AL amyloidosis confirmed by positive Congo red staining with green birefringence on polarized light microscopy in an organ outside the bone marrow and evidence of a measurable clonal plasma cell disease that requires active treatment.
 - An underlying plasma cell disorder can be identified by one of the following: clonal plasma cells in the BM, monoclonal protein in the serum or urine, or abnormal free light chain ratio.
- ... and 8 more (see full listing online)

Exclusion (39)

- Prior treatment with CAR T therapy directed at any target.
 - Any therapy that is targeted to BCMA.
 - Stroke or seizure within 6 months of signing ICF.
 - Bone marrow plasma cells \>30% and clinically symptomatic multiple myeloma with end organ damage (i.e. lytic bone lesions).
 - New York Heart Association Heart Failure Class III or Class IV.
- ... and 34 more (see full listing online)

Locations (18 total)

Sutter Health Alta Bates, Berkeley, California, United States
City of Hope, Duarte, California, United States
University of California Los Angeles, Los Angeles, California, United States
... and 15 more locations

<https://clinicaltrials.gov/study/NCT06097832>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).